Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Farhad Ravandi; Rita Assi; Naval Daver; Christopher B Benton; Tapan Kadia; Philip A Thompson; Gautam Borthakur; Yesid Alvarado; Elias J Jabbour; Marina Konopleva; Koichi Takahashi; Steven Kornblau; Courtney D DiNardo; Zeev Estrov; Wilmer Flores; Sreyashi Basu; James Allison; Padmanee Sharma; Sherry Pierce; Allison Pike; Jorge E Cortes; Guillermo Garcia-Manero; Hagop M Kantarjian

doi:10.1016/s2352-3026(19)30114-0

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

The Lancet Haematology ◽

10.1016/s2352-3026(19)30114-0 ◽

2019 ◽

Vol 6 (9) ◽

pp. e480-e488 ◽

Cited By ~ 19

Author(s):

Farhad Ravandi ◽

Rita Assi ◽

Naval Daver ◽

Christopher B Benton ◽

Tapan Kadia ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Newly Diagnosed ◽

Phase 2 Study ◽

Acute Myeloid

Download Full-text

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(21)00192-7 ◽

2021 ◽

Vol 8 (8) ◽

pp. e552-e561 ◽

Cited By ~ 1

Author(s):

Tapan M Kadia ◽

Patrick K Reville ◽

Gautam Borthakur ◽

Musa Yilmaz ◽

Steven Kornblau ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽

Acute Myeloid

Download Full-text

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00362-9 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1691-1699 ◽

Cited By ~ 191

Author(s):

Christoph Röllig ◽

Hubert Serve ◽

Andreas Hüttmann ◽

Richard Noppeney ◽

Carsten Müller-Tidow ◽

...

Keyword(s):

Randomised Controlled Trial ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Standard Therapy ◽

Controlled Trial ◽

Phase 2 ◽

Newly Diagnosed ◽

Multicentre Phase ◽

Randomised Controlled ◽

Acute Myeloid

Download Full-text

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70037-8 ◽

2013 ◽

Vol 14 (4) ◽

pp. 354-362 ◽

Cited By ~ 26

Author(s):

Jorge Cortes ◽

Eric Feldman ◽

Karen Yee ◽

David Rizzieri ◽

Anjali S Advani ◽

...

Keyword(s):

Elderly Patients ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Dosing Regimens ◽

Acute Myeloid

Download Full-text

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high‐risk myelodysplastic syndrome

European Journal Of Haematology ◽

10.1111/ejh.13196 ◽

2019 ◽

Vol 102 (3) ◽

pp. 218-226

Author(s):

Marie Warny ◽

Jens Helby ◽

Henrik Sengeløv ◽

Børge G. Nordestgaard ◽

Henrik Birgens ◽

...

Keyword(s):

Bone Marrow ◽

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Telomere Length ◽

Mononuclear Cell ◽

Bone Marrow Mononuclear Cell ◽

Acute Myeloid

Download Full-text

Eltrombopag in patients with high-risk myelodysplastic syndrome or acute myeloid leukaemia: cautious optimism

The Lancet Haematology ◽

10.1016/s2352-3026(15)00200-8 ◽

2015 ◽

Vol 2 (10) ◽

pp. e396-e397 ◽

Cited By ~ 1

Author(s):

Rena Buckstein

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Acute Myeloid

Download Full-text

DUPLICATE - A Randomised Trial for Patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndrome Aged 60 or over

http://isrctn.org/> ◽

10.1186/isrctn42347148 ◽

2013 ◽

Author(s):

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Randomised Trial ◽

Acute Myeloid

Download Full-text

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology ◽

10.1016/s2352-3026(20)30210-6 ◽

2020 ◽

Vol 7 (10) ◽

pp. e724-e736 ◽

Cited By ~ 7

Author(s):

Courtney D DiNardo ◽

Abhishek Maiti ◽

Caitlin R Rausch ◽

Naveen Pemmaraju ◽

Kiran Naqvi ◽

...

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Intensive Chemotherapy ◽

Phase 2 ◽

Newly Diagnosed ◽

Single Centre ◽

Phase 2 Trial ◽

Acute Myeloid

Download Full-text

A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome

http://isrctn.org/> ◽

10.1186/isrctn31682779 ◽

2013 ◽

Author(s):

Nigel Russell

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Older Patients ◽

Acute Myeloid

Download Full-text

Pilot safety/tolerability study of Lenalidomide administered as monotherapy and in combination with standard chemotherapy for Acute Myeloid Leukaemia/high-risk myelodysplastic syndrome with structural abnormalities of chromosome 5

http://isrctn.org/> ◽

10.1186/isrctn58492795 ◽

2012 ◽

Author(s):

David Bowen

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukaemia ◽

Chromosome 5 ◽

Standard Chemotherapy ◽

Structural Abnormalities ◽

Acute Myeloid

Download Full-text

A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age

British Journal of Haematology ◽

10.1111/bjh.13437 ◽

2015 ◽

Vol 170 (3) ◽

pp. 349-355 ◽

Cited By ~ 6

Author(s):

Sarah A. Buckley ◽

Raya Mawad ◽

Ted A. Gooley ◽

Pamela S. Becker ◽

Vicky Sandhu ◽

...

Keyword(s):

High Risk ◽

Acute Myeloid Leukaemia ◽

Myelodysplastic Syndrome ◽

Phase I ◽

Myeloid Leukaemia ◽

Low Dose ◽

Previously Treated ◽

Low Dose Cytarabine ◽

Acute Myeloid

Download Full-text